| Robert S Benintendi, MD | |
|
2055 Hospital Drive, Suite 130, Batavia, OH 45103-9518 | |
| (513) 732-0870 | |
| (513) 732-0873 |
| Full Name | Robert S Benintendi |
|---|---|
| Gender | Male |
| Speciality | Obstetrics & Gynecology |
| Location | 2055 Hospital Drive, Batavia, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265437313 | NPI | - | NPPES |
| 0267198 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 35024889 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Robert S Benintendi, MD 5400 Dupont Circle, Suite A, Milford, OH 45150 Ph: (513) 576-7700 | Robert S Benintendi, MD 2055 Hospital Drive, Suite 130, Batavia, OH 45103-9518 Ph: (513) 732-0870 |
News Archive
There is substantial evidence that indoor tanning is associated with increased risk of skin cancer – the most common type of cancer nationwide according to the American Cancer Society. Public health officials and researchers have become increasingly concerned about the health risks posed by indoor tanning.
In the emerging biosimilar market, biosimilar antibodies are being developed to treat conditions currently addressed by their original, targeted biological therapy. Only a few biosimilars are approved by the EMA, and just one has been approved by the FDA. In a review article, researchers used the clinical development data from one drug to explore the broader benefits and risks of these cost-effective, but as yet unfamiliar treatment options.
Repros Therapeutics today announced that the Company has entered into an amendment with the National Institutes of Health (NIH) to its existing exclusive license for Proellex® that revises the existing milestones and dates for performance to provide additional time to lift the current clinical hold on Proellex or select a second generation molecule for further development from the family of anti-progestational agents covered by the license.
EpiCept Corporation announced today that it has entered into an exclusive commercialization agreement for Ceplene® (histamine dihydrochloride) with Meda AB, a leading international specialty pharmaceutical company based in Stockholm. Ceplene is EpiCept's novel therapy approved in the European Union with orphan drug status for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first remission.
› Verified 2 days ago
Tifany Nyssa Nolan, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2055 Hospital Dr, Suite 130, Batavia, OH 45103 Phone: 513-732-0870 Fax: 513-732-0873 | |
Dr. Sherry L Johnson, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2055 Hospital Dr Ste 220, Batavia, OH 45103 Phone: 513-732-0870 Fax: 513-732-0873 |